The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
 
Ciara Catherine Maria O'Sullivan
Research Funding - Bavarian Nordic (Inst); Biovica (Inst); Lilly Medical (Inst); Minneamrita Therapeutics (Inst); Seagen (Inst)
(OPTIONAL) Uncompensated Relationships - Lilly; Seagen
 
Karla V. Ballman
Consulting or Advisory Role - Agenus; ARIAD; Medtronic; Takeda
Patents, Royalties, Other Intellectual Property - Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Janssen Oncology; Lilly; Sanofi
 
Linda Mackie McCall
No Relationships to Disclose
 
Tyler J. Zemla
No Relationships to Disclose
 
Anna Weiss
Research Funding - Myriad Genetics
 
Melissa Mitchell
No Relationships to Disclose
 
Victoria Susana Blinder
No Relationships to Disclose
 
Nadine M. Tung
Research Funding - AstraZeneca (Inst)
 
William Johnson Irvin
Research Funding - Altor BioScience (Inst); Altor BioScience (Inst); Boston Biomedical (Inst); Genomic Health (Inst); Luitpold Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst)
 
Myounghee Lee
No Relationships to Disclose
 
Matthew P. Goetz
Consulting or Advisory Role - bioTheranostics; Biovica; Context Therapeutics; Eisai; Genomic Health; Lilly; Novartis; Pfizer; Sermonix Pharmaceuticals
Research Funding - Lilly (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Development of Human Tumor Xenografts from Women with Breast Cancer Treated with Neoadjuvant Chemotherapy (Inst); Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer; METHODS AND MATERIALS FOR USING BUTYRYLCHOLINESTERASES TO TREAT CANCER
Travel, Accommodations, Expenses - Lilly
 
William Fraser Symmans
Stock and Other Ownership Interests - Delphi Diagnostics; Eiger BioPharmaceuticals; ISIS Pharmaceuticals; Nuvera Biosciences
Consulting or Advisory Role - Almac Diagnostics; Merck
Patents, Royalties, Other Intellectual Property - Intellectual property; Intellectual Property (expired)
Travel, Accommodations, Expenses - Luminex; Merck
(OPTIONAL) Uncompensated Relationships - Delphi Diagnostics
 
Virginia F. Borges
Consulting or Advisory Role - Seagen
Research Funding - AstraZeneca (Inst); Olema Oncology (Inst); oncosec (Inst); Seagen (Inst)
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I); Freeline Therapeutics (I)
Leadership - AMAG Pharmaceuticals (I); Freeline Therapeutics (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I); Freeline Therapeutics (I); vertex (I)
Honoraria - AstraZeneca; Celltrion; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Context Therapeutics; Daiichi Sankyo; Genentech/Roche; Ionis Pharmaceuticals; Macrogenics; Merck; Novartis; Seagen; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst)
 
Ann H. Partridge
Patents, Royalties, Other Intellectual Property - I receive small royalty payments for co-authoring the breast cancer survivorship section of UpToDate
Travel, Accommodations, Expenses - Novartis
 
Lisa A. Carey
Research Funding - Abbvie (Inst); Immunomedics (Inst); NanoString Technologies (Inst); Novartis (Inst); Seagen (Inst); Syndax (Inst); Veracyte (Inst)
Patents, Royalties, Other Intellectual Property - Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme. (I)
(OPTIONAL) Uncompensated Relationships - Aptitude Health (Inst); AstraZeneca/Daiichi Sankyo (Inst); Exact Sciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Sanofi (Inst)